Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
NCT ID: NCT03017573
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1050 participants
INTERVENTIONAL
2017-01-06
2032-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. if eligible for surgery :
* at surgery (blood + tumor and nodes)
* after surgery (blood)
* 6 months after surgery if non recurrence (Blood)
* before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes if possible)
* before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)
* at progression (blood + tumor biopsie and nodes if possible)
2. if eligible for neoadjuvant chemotherapy :
* before neoadjuvant therapy (blood + tumor biopsie and nodes)
* during neoadjuvant therapy (post cycle 1) (blood)
* at the time of surgery (blood + tumor and nodes)
* 6 months after surgery if non recurrence (Blood)
* before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes)
* before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)
* at progression (blood + tumor biopsie and nodes)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tumor and blood sampling
Patients will have a biopsy or a surgery and blood sampling at different time points.
Tumor biopsies / Tumor surgery
Tumoral tissues samples must be collected at different times points :
* at the time of surgery
* before first cycle of adjuvant treatment (if possible)
* at progression (if possible)
OR
* before neoadjuvant therapy
* at the time of surgery
* before first cycle of adjuvant treatment (if possible)
* at progression (if possible)
Blood withdrawal
Blood samples must be collected at different times points :
* at the time of surgery or before the beginning of chemoradiotherapy
* after surgery or after chemoradiotherapy
* 6 months after surgery if non recurrence
* before first cycle of adjuvant treatment or before radiotherapy
* before second cycle of adjuvant treatment or after radiotherapy
* at progression
OR
* before neoadjuvant therapy
* during neoadjuvant therapy (post cycle 1)
* at the time of surgery
* 6 months after surgery if non recurrence
* before first cycle of adjuvant treatment or before radiotherapy
* before second cycle of adjuvant treatment or after radiotherapy
* at progression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumor biopsies / Tumor surgery
Tumoral tissues samples must be collected at different times points :
* at the time of surgery
* before first cycle of adjuvant treatment (if possible)
* at progression (if possible)
OR
* before neoadjuvant therapy
* at the time of surgery
* before first cycle of adjuvant treatment (if possible)
* at progression (if possible)
Blood withdrawal
Blood samples must be collected at different times points :
* at the time of surgery or before the beginning of chemoradiotherapy
* after surgery or after chemoradiotherapy
* 6 months after surgery if non recurrence
* before first cycle of adjuvant treatment or before radiotherapy
* before second cycle of adjuvant treatment or after radiotherapy
* at progression
OR
* before neoadjuvant therapy
* during neoadjuvant therapy (post cycle 1)
* at the time of surgery
* 6 months after surgery if non recurrence
* before first cycle of adjuvant treatment or before radiotherapy
* before second cycle of adjuvant treatment or after radiotherapy
* at progression
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy
2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy
3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery
4. Newly diagnosed treatment-naïve cervical cancer patients (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2).
5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment
2. Male or female patients ≥ 18 years of age
3. Signed informed consent
Exclusion Criteria
2. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
3. Individually deprived of liberty or placed under the authority of a tutor
4. Patients not affiliated to the Social Security System
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Curie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christophe LE TOURNEAU, Prof.
Role: PRINCIPAL_INVESTIGATOR
Institut Curie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Bergonie
Bordeaux, , France
Centre Oscar Lambret
Lille, , France
Centre Leon Berard
Lyon, , France
Institut Curie
Paris, , France
Institut Curie Hopital Rene Huguenin
Saint-Cloud, , France
Institut de Cancérologie de Lorraine - Nancy
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Adeline PETIT, MD
Role: primary
Camille PASQUESOONE, MD
Role: primary
Nicolas CHOPIN, MD
Role: primary
Role: backup
Edith BORCOMAN, MD
Role: primary
Nicolas POUGET, MD
Role: primary
Romina MASTRONICOLA, M
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Hoffmann C, Noel F, Grandclaudon M, Massenet-Regad L, Michea P, Sirven P, Faucheux L, Surun A, Lantz O, Bohec M, Ye J, Guo W, Rochefort J, Klijanienko J, Baulande S, Lecerf C, Kamal M, Le Tourneau C, Guillot-Delost M, Soumelis V. PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity. Nat Commun. 2022 Apr 13;13(1):1983. doi: 10.1038/s41467-022-29516-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC 2016-03
Identifier Type: -
Identifier Source: org_study_id